<DOC>
	<DOCNO>NCT00419042</DOCNO>
	<brief_summary>The purpose study non small-cell lung cancer stage IV et IIIB ( T4 pleural effusion ) elderly dependent patient evaluation sequence Gemcitabine first line follow Erlotinib progression versus Erlotinib first line follow Gemcitabine progression</brief_summary>
	<brief_title>Elderly Dependent Patients With Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>A multicenter phase II trial , prospective , randomize , open , non comparative</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age &gt; 65 Comorbidities score , PS frailty score accord table 1 No dementia , faecal urinary incontinence , repeat fall ADL = 0 , IADL = 01 Life expectancy least 12 week Creatinin clearance &gt; = 30 ml/mn ( accord CockcroftsGault formula ) Competency give write informed consent Haematological function follow : neutrophile count &gt; 1.5 x 109/l platelet &gt; 100 x 109/l hemoglobin &gt; 9,5 g/dl Hepatic function follow : Bilirubin &lt; 1,25 LNS ASAT / ALAT &lt; 5 x NAlcPh &lt; 5 x N PS &lt; 3 cerebral metastasis eligible asymptomatic Histologically cytologically confirm NSCLC Stage IV/IIIB4 ( T4 pleural effusion ) No prior chemotherapy relapse previous NSCLC treat surgery radiotherapy eligible , target measurable initial radiotherapy field cytological histological proof At least one measurable target lesion RECIST guideline symptomatic cerebral metastasis Any severe comorbidity calculate Charlson score accord table 1 ADL &gt; 0 IADL &gt; 1 performance status &gt; 2 ( ECOG ) peripheral neuropathy grade 2 dementia , repeat fall , urinary faecal incontinence contraindication corticosteroid contra indication product study unwilling unable comply study requirement , personal , family , sociologic , geographic reason inability subject give write informed consent lack liberty follow legal administrative decision hypersensitivity polysorbate hypersensitivity erlotinib excipients product unusual hereditary disorder , galactosemia , deficit lactase syndrome malabsorption glucose galactose participation concomitant clinical trial bronchioloalveolar neuroendocrine composite carcinoma superior vena cava syndrome</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>cancer</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>None small-cell lung cancer</keyword>
</DOC>